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Myostatin is a transforming growth factor-ß family member that normally acts to limit skeletal muscle growth. Mice genetically
engineered to lack myostatin activity have about twice the amount of muscle mass throughout the body, and similar effects
are seen in cattle, sheep, dogs, and a human with naturally occurring loss-of-function mutations in the myostatin gene. Hence,
there is considerable interest in developing agents capable of inhibiting myostatin activity for both agricultural and human
therapeutic applications. We previously showed that the myostatin binding protein, follistatin, can induce dramatic increases
in muscle mass when overexpressed as a transgene in mice. In order to determine whether this effect of follistatin results solely
from inhibition of myostatin activity, I analyzed the effect of this transgene in myostatin-null mice. Mstn
2/2 mice carrying
a follistatin transgene had about four times the muscle mass of wild type mice, demonstrating the existence of other
regulators of muscle mass with similar activity to myostatin. The greatest effect on muscle mass was observed in offspring of
mothers homozygous for the Mstn mutation, raising the possibility that either myostatin itself or a downstream regulator may
normally be transferred from the maternal to fetal circulations. These findings demonstrate that the capacity for increasing
muscle growth by manipulating TGF-ß signaling pathways is much more extensive than previously appreciated and suggest
that muscle mass may be controlled at least in part by a systemic mode of action of myostatin.
Citation: Lee S-J (2007) Quadrupling Muscle Mass in Mice by Targeting TGF-ß Signaling Pathways. PLoS ONE 2(8): e789. doi:10.1371/
journal.pone.0000789
INTRODUCTION
Myostatin (MSTN) is a transforming growth factor-ß (TGF-ß)
family member that plays a critical role in regulating skeletal
muscle mass [1]. Mice engineered to carry a deletion of the Mstn
gene have about a doubling of skeletal muscle mass throughout the
body as a result of a combination of muscle fiber hyperplasia and
hypertrophy [2]. Moreover, loss of myostatin activity resulting
either from postnatal inactivation of the Mstn gene [3,4] or
following administration of various myostatin inhibitors to wild
type adult mice [5–7] can also lead to significant muscle growth.
Hence, myostatin appears to play as least two distinct roles, one to
regulate the number of muscle fibers that are formed during
development and a second to regulate growth of muscle fibers
postnatally. The function of myostatin appears to have been
conserved across species, as inactivating mutations in the
myostatin gene have been demonstrated to cause increased
muscling in cattle [8–11] , sheep [12], dogs [13] and humans
[14]. As a result, there has been considerable effort directed at
developing strategies to modulate myostatin activity in clinical
settings where enhancing muscle growth may be beneficial. In this
regard, loss of myostatin activity has been demonstrated to
improve muscle mass and function in dystrophic mice [15–17] and
to have beneficial effects on fat and glucose metabolism in mouse
models of obesity and type II diabetes [18].
Myostatin is synthesized as a precursor protein that undergoes
proteolytic processing to generate an N-terminal propeptide and
a C-terminal dimer, which is the biologically active species.
Following proteolytic processing, the propeptide remains bound to
the C-terminal dimer and maintains it in an inactive, latent
complex [6,19,20], which represents one of the major forms of
myostatin that circulates in the blood [21,22]. In addition to the
propeptide, other binding proteins are capable of regulating
myostatin activity in vitro, including follistatin [19,21], FLRG [22],
and Gasp-1 [23]. We previously showed that follistatin can also
block myostatin activity in vivo; specifically, we showed that
follistatin can ameliorate the cachexia induced by high level
expression of myostatin in nude mice [21] and that transgenic
mice expressing follistatin in muscle have dramatic increases in
muscle mass [19]. Here, I show that overexpression of follistatin
can also cause substantial muscle growth in mice lacking
myostatin, demonstrating that other TGF-ß related ligands
normally cooperate with myostatin to suppress muscle growth
and that the capacity for enhancing muscle growth by targeting
this signaling pathway is much larger than previously appreciated.
RESULTS
Increased muscle mass in transgenic mice
expressing FLRG
Previous studies have identified several proteins that are normally
found in a complex with myostatin in the blood [22,23]. One of
these is the follistatin related protein, FLRG, which has been
demonstrated to be capable of inhibiting myostatin activity in vitro.
To determine whether FLRG can also inhibit myostatin activity in
vivo, I generated a construct in which the FLRG coding sequence
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enhancer. From pronuclear injections of this construct, a total of
four transgenic mouse lines (Z111A, Z111B, Z116A, and Z116B)
were obtained containing independently segregating insertion
sites. Each of these four transgenic lines was backcrossed at least 6
times to C57 BL/6 mice prior to analysis in order to control for
genetic background effects. Northern analysis revealed that in
three of these lines the transgene was expressed in skeletal muscles
but not in any of the non-skeletal muscle tissues examined
(Figure 1); in the fourth line, Z111B, the expression of the
transgene was below the level of detection in these blots. As shown
in Table 1, all four lines exhibited significant increases in muscle
weights compared to wild type control mice. These increases were
observed in all four muscles that were examined as well as in both
sexes. Moreover, the rank order of magnitude of these increases
correlated with the rank order of expression levels of the transgene;
in the highest-expressing line, Z116A, muscle weights were
increased by 57–81% in females and 87–116% in males compared
to wild type mice. Hence, FLRG is capable of increasing muscle
growth in a dose-dependent manner when expressed as a transgene
in skeletal muscle.
To determine whether the FLRG transgene was causing
increased muscle growth by blocking myostatin activity, I
examined the effect of combining the FLRG transgene with
a loss-of-function mutation in the myostatin gene. To date, using
the Z116A line, I have not been able to generate mice that are
both positive for the transgene and homozygous for the myostatin
deletion mutation. However, I did obtain a number of female
Z116A transgenic mice that were heterozygous for the myostatin
mutation, and as shown in Table 1 and Figure 2a, these mice
Figure 1. Northern analysis of FLRG transgenic mice. Total RNA was
prepared from various tissues from 10-week old female mice,
electrophoresed, blotted, and probed with a fragment derived from
SV40 corresponding to the processing/polyadenylation sequences
present in the transgenic construct. The blots were re-hybridized with
a probe for the S26 ribosomal protein to control for loading.
doi:10.1371/journal.pone.0000789.g001
Table 1. Muscle weights (mg) of FLRG (Z) and follistatin (F66) transgenic mice.
..................................................................................................................................................
offspring sex mother n pectoralis triceps quadriceps gastrocnemius
1 Mstn
+/+ F Mstn
+/+ 22 47.360.8 68.261.1 142.861.7 95.961.3
2 Mstn
+/2 F Mstn
+/2 15 63.060.8
a 90.061.5
a 176.662.4
a 122.861.6
a
3 Mstn
2/2 F Mstn
+/2 10 105.763.4
a 148.763.7
a 266.966.7
a 181.163.8
a
4 Z111B F N/A 11 53.561.5
b 75.362.2
b 151.264.2 102.762.8
c
5 Z116B F N/A 15 64.961.2
a 98.362.0
a 200.263.8
a 141.563.1
a
6 Z111A F N/A 12 69.863.1
a 105.464.6
a 223.968.3
a 160.666.7
a
7 Z116A F N/A 11 74.462.1
a 116.663.8
a 236.565.8
a 173.665.0
a
8 Z116A, Mstn
+/2 F Mstn
+/2 89 3 . 0 61.8
a 151.464.4
a 295.467.3
a,d 224.966.6
a,e
9 Mstn
+/+ M Mstn
+/+ 19 73.561.3 91.561.6 190.063.2 129.461.7
10 Mstn
+/2 M Mstn
+/2 13 94.362.0
f 127.162.6
f 243.265.4
f 167.563.2
f
11 Mstn
2/2 M Mstn
+/2 10 190.867.1
f 236.165.2
f 390.169.4
f 272.664.9
f
12 Z111B M N/A 10 78.561.8
g 99.462.2
h 199.963.9 135.062.9
13 Z116B M N/A 11 98.663.9
f 131.164.3
f 267.168.5
f 188.865.3
f
14 Z111A M N/A 9 113.766.4
f 156.469.5
f 307.4615.5
f 221.3610.4
f
15 Z116A M N/A 11 137.366.7
f 196.565.9
f 370.5614.0
f 279.5610.4
f
16 F66, Mstn
+/+ M Mstn
+/+ 20 121.962.3
f 182.665.0
f 440.6611.1
f 295.365.6
f
17 F66, Mstn
+/+ M Mstn
+/2 23 126.562.6 186.664.5 480.7611.6
i 314.766.7
i
18 F66, Mstn
+/2 M Mstn
+/2 12 185.466.1
j 307.268.9
j 583.7619.2
j 384.3610.9
j
19 F66, Mstn
+/2 M Mstn
2/2 11 200.365.9 306.569.6 637.4612.5
k 439.369.8
l
20 F66, Mstn
2/2 M Mstn
+/2 14 280.167.7
l 383.769.2
l 619.7616.0
l 492.1613.4
l
21 F66, Mstn
2/2 M Mstn
2/2 15 320.169.0
m,o 412.164.6
m,o 668.968.2
n,o 529.6610.1
n,o
ap,0.001 vs. line 1,
bp,0.01 vs. line 1,
cp,0.05 vs. line 1,
dp,0.01 vs. line 3,
ep,0.001 vs. line 3,
fp,0.001 vs. line 9,
gp,0.05 vs. line 9,
hp,0.01 vs. line 9,
ip,0.05 vs. line
16,
jp,0.001 vs. line 17,
kp,0.05 vs. line 18,
lp,0.001 vs. line 18,
mp,0.01 vs. line 20,
np,0.05 vs. line 20,
op,0.001 vs. line 11
doi:10.1371/journal.pone.0000789.t001
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Quadrupling Muscle Mass: Mice
PLoS ONE | www.plosone.org 2 August 2007 | Issue 8 | e789exhibited further increases in muscle weights compared to Z116A
mice that were wild type for myostatin. Most importantly, in two
of the muscles that were examined (quadriceps and gastrocnemius)
the observed increases were also greater than those seen in Mstn
2/
2 mice lacking the transgene. Based on this finding, it appears that
myostatin cannot be the sole target for FLRG in the transgenic
mice and, therefore, that additional ligands must be capable of
suppressing muscle growth in vivo.
Effect of follistatin in Mstn null mice
Because I was unable to examine the effect of overexpressing
FLRG in the complete absence of myostatin, it was difficult to
ascertain the relative importance of these additional ligands
compared to myostatin in regulating muscle mass. However, I
carried out a similar set of experiments utilizing follistatin
transgenic mice, which demonstrated that these additional ligands
do play a major role in suppressing muscle growth. In previous
studies, we had generated several transgenic founders expressing
follistatin from a myosin light chain promoter/enhancer [19]. I
was able to establish a transgenic line from one of these founders
(F66), and I backcrossed this line extensively to C57 BL/6 mice for
subsequent analysis. In this line, the transgene was most likely
located on the Y chromosome, as the transgene was transmitted to
all of the male offspring and none of the female offspring. F66
transgenic mice were mated with Mstn mutant mice, and F66/
Mstn
+/2 males were then mated with either Mstn
+/2 or Mstn
2/2
females. As shown in Table 1, the presence of one or two Mstn
mutant alleles in combination with the F66 transgene resulted in
increasingly more muscle mass than seen in F66 transgenic mice
that were wild type for Mstn. Moreover, muscle weights in either
F66/Mstn
+/2 or F66/Mstn
2/2 mice were dramatically higher than
in Mstn
2/2 mice lacking the F66 transgene. In the most extreme
case, muscle weights in F66/Mstn
2/2 mice were increased by
250–350% from those seen in wild type mice (Figures 2b and 3).
Hence, the presence of the F66 transgene in a Mstn
2/2
background caused yet another doubling of muscle weights,
resulting in mice with approximately quadruple the normal
amount of muscle. These findings demonstrate that like FLRG,
follistatin must be exerting its effect on muscle growth by targeting
other ligands in addition to myostatin and that the effect of
blocking these other ligands is comparable in magnitude to that
resulting from loss of myostatin.
In previous studies, we showed that the increase in muscle mass
in Mstn
2/2 mice results from a combination of increased fiber
numbers and increased fiber sizes [2]. To determine whether the
same is true for the additional muscle mass seen upon introduction
of the F66 transgene, I carried out morphometric analysis of the
gastrocnemius/plantaris muscles. As shown in Table 2 and
Figure 2c, total fiber number and mean fiber diameter were
increased by about 48% and 19%, respectively, in Mstn
2/2 mice
compared to wild type mice. As the cross-sectional area of the
muscle would be expected to be roughly proportional to the square
of the diameter, increased fiber diameter in Mstn
2/2 mice would
correspond to an approximately 43% increase in fiber mass.
Hence, muscle fiber hyperplasia and hypertrophy appear to
contribute roughly equally to give the overall doubling of
gastrocnemius/plantaris mass in Mstn
2/2 mice. In contrast,
a similar analysis of F66 transgenic mice revealed that although
total fiber number was increased slightly (16%), the overall
increase in gastrocnemius/plantaris mass resulted almost entirely
from muscle fiber hypertrophy (93% increase in cross-sectional
area). In mice in which the F66 transgene was combined with the
Mstn null mutation, the two phenotypes appeared to be additive;
that is, the quadrupling of muscle mass in F66/Mstn
2/2 mice
resulted from an approximately 73% increase in fiber number and
117% increase in fiber cross-sectional area. These results suggest
that the additional muscle mass induced by follistatin in Mstn null
mice results from inhibition of additional ligands that act
predominantly to regulate muscle fiber growth.
Figure 2. Muscle weight increases in (A) female Mstn mutant and
Z116A transgenic mice and (B) male Mstn mutant and F66 transgenic
mice. Numbers represent percent increases relative to wild type mice
and were calculated from the data shown in Table 1. (C) Distribution of
fiber diameters. Gray bars represent muscles from wild type mice, and
red bars represent muscles from Mstn
2/2, F66, and F66/Mstn
2/2 mice.
doi:10.1371/journal.pone.0000789.g002
Quadrupling Muscle Mass: Mice
PLoS ONE | www.plosone.org 3 August 2007 | Issue 8 | e789Maternal effect of the Mstn null mutation
In the experiments with F66 transgenic mice, a consistent finding
was that muscle weights were higher in animals of the same
genotype if they arose from crosses in which the mother had fewer
functional Mstn alleles (Table 1). This maternal effect was observed
to some extent in all of the muscles examined but was most
pronounced in the quadriceps and gastrocnemius. For example,
muscle weights of F66/Mstn
+/+ males obtained from crosses with
Mstn
+/2 females were higher than those of F66/Mstn
+/+ males
obtained from crosses with Mstn
+/+ females. Similarly, muscle
weights of F66/Mstn
+/2 males obtained from crosses with Mstn
2/
2 females were higher than those of F66/Mstn
+/2 males obtained
from crosses with Mstn
+/2 females. The most dramatic effects were
observed in F66/Mstn
2/2 mice obtained from crosses with Mstn
2/
2 females, in which muscle weights were approximately
quadrupled compared to wild type mice.
To determine whether this maternal effect was specific to the
presence of the F66 transgene, I carried out a variety of crosses of
Mstn mutant mice lacking the transgene. As shown in Table 3, the
maternal effect on muscle weights was observed in these crosses as
well. In virtually every case, mice with identical genotypes
exhibited higher muscle weights if the mother had fewer functional
Mstn alleles. The most clear cut results were obtained in analyses of
Mstn
+/2 offspring derived from crosses of Mstn
+/+ males with
Mstn
2/2 females, which showed significantly higher muscle
weights than Mstn
+/2 offspring derived from crosses of Mstn
2/2
males with Mstn
+/+ females. Hence, the maternal effect on muscle
mass was not dependent on the presence of the F66 transgene.
Conceivably, this maternal effect could result from transfer of
myostatin or a downstream mediator either prenatally from the
maternal to fetal circulations or postnatally from the mother to the
offspring during nursing; in this respect, myostatin mRNA has
been reported to be expressed in the mammary gland of lactating
pigs [24]. To distinguish these two possibilities, I analyzed the
effect of transferring neonates obtained from crosses with mothers
of one Mstn genotype to foster mothers of a different Mstn
genotype. In these experiments, all transfers were carried out using
neonatal mice less than 24 hours old to mothers that had delivered
their own litters also within the previous 24 hours. In order to
control for effects of the transfer process per se, I also carried out
transfers of neonates obtained from crosses with mothers of one
Mstn genotype to foster mothers of the same Mstn genotype. As
shown in Table 4, mice of a given genotype and parentage
exhibited comparable muscle weights regardless of the genotype of
the foster mothers. Hence, if there is a mediator of muscle mass
that is transferred through the milk, I was not able to detect any
resultant effects on muscle mass in these experiments. Taken
together, these results suggest that the maternal effect on muscle
mass results most likely from prenatal transfer of some mediator
from mother to fetus, perhaps myostatin itself.
DISCUSSION
Based on the data presented here, two important conclusions can
be drawn. The first is that the Mstn loss-of-function mutation
exerts a maternal effect such that muscle mass of the fetus is
influenced by the number of functional Mstn alleles in the mother.
Specifically, I show that offspring with identical Mstn genotypes
have higher muscle weights if the mother has fewer functional
Mstn alleles. This finding taken together with the results of cross
fostering experiments suggest that muscle mass can be influenced
by prenatal transfer of some mediator from mother to fetus;
although myostatin itself is the most obvious candidate for this
mediator, additional experiments will be required to prove this
definitively.
Figure 3. Comparison of wild type and F66/Mstn
2/2 mice.
doi:10.1371/journal.pone.0000789.g003
Quadrupling Muscle Mass: Mice
PLoS ONE | www.plosone.org 4 August 2007 | Issue 8 | e789We showed previously that myostatin circulates in the blood
and that systemic effects can be achieved by implanting myostatin-
expressing cells into a single site in the lower limb [21]; however,
there have been no experiments that have demonstrated
conclusively that myostatin normally acts systemically. The
demonstration that maternal effects can be seen in offspring of
mice lacking myostatin is consistent with the possibility that the
circulating myostatin protein can enter the active pool. If
myostatin does act systemically, the implication would be that
local control of muscle growth can be influenced at least in part by
myostatin being produced elsewhere in the body and that
myostatin functions precisely as a chalone, as originally hypoth-
esized by Bullough [25,26] for the control for tissue growth in
general. This is a critical issue, as it relates to the fundamental
reason that the control of muscle growth may have evolved into
this rather complex regulatory system. In this respect, I speculated
previously that perhaps the myostatin regulatory system may serve
two distinct functions, one to regulate local growth of muscle in
Table 2. Morphometric analysis of gastrocnemius/plantaris muscles.
..................................................................................................................................................
genotype n total fiber number
relative fiber
number
mean fiber
diameter (mm)
relative fiber
diameter
relative cross-
sectional area
a
Mstn
+/+ 48 4 5 1 6505 1.00 41.361.0 1.00 1.00
Mstn
2/2 4 1248861251
b 1.48 49.362.2
b 1.19 1.43
F66, Mstn
+/+ 39 8 3 8 684
b 1.16 57.461.1
c 1.39 1.93
F66, Mstn
2/2 2 145936849
b 1.73 60.861.1
c 1.47 2.17
acalculated as relative fiber diameter squared,
bp,0.05 vs. Mstn
+/+,
cp,0.001 vs. Mstn
+/+
doi:10.1371/journal.pone.0000789.t002
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Table 3. Maternal effect of Mstn null mutation.
..................................................................................................................................................
line Mstn sex father mother n pectoralis triceps quadriceps gastrocnemius
1 +/+ F Mstn
+/+ Mstn
+/+ 22 47.360.8 68.261.1 142.861.7 95.961.3
2 +/+ F Mstn
+/2 Mstn
+/2 15 51.261.4
a 70.761.4 147.963.2 101.362.3
a
3 +/2 F Mstn
2/2 Mstn
+/+ 19 59.861.1 84.361.6 165.462.6 113.461.3
4 +/2 F Mstn
+/2 Mstn
+/2 15 63.060.8
b 90.061.5
b 176.662.4
c 122.861.6
d
5 +/2 F Mstn
+/+ Mstn
2/2 19 65.362.5
c 93.762.8
d 181.365.0
d 123.663.2
d
6 2/2 F Mstn
+/2 Mstn
+/2 10 105.763.4 148.763.7 266.966.7 181.163.8
7 2/2 F Mstn
2/2 Mstn
2/2 19 110.661.9 156.963.1 278.664.9 192.563.6
e
8 +/+ M Mstn
+/+ Mstn
+/+ 19 73.561.3 91.561.6 190.063.2 129.461.7
9 +/+ M Mstn
+/2 Mstn
+/2 13 79.162.2
f 99.463.4
f 198.564.9 137.063.0
f
10 +/2 M Mstn
2/2 Mstn
+/+ 28 93.661.9 120.162.3 230.064.0 158.862.4
11 +/2 M Mstn
+/2 Mstn
+/2 13 94.362.0 127.162.6 243.265.4 167.563.2
g
12 +/2 M Mstn
+/+ Mstn
2/2 21 101.761.7
h 133.462.2
i 252.564.1
i 168.262.5
h
13 2/2 M Mstn
+/2 Mstn
+/2 10 190.867.1 236.165.2 390.169.4 272.664.9
14 2/2 M Mstn
2/2 Mstn
2/2 17 193.763.6 240.763.3 397.365.6 277.764.1
Numbers represent muscle weights (mg).
ap,0.05 vs. line 1,
bp,0.05 vs. line 3,
cp,0.01 vs. line 3,
dp,0.001 vs. line 3,
ep,0.05 vs. line 6,
fp,0.05 vs. line 8,
gp,0.05 vs.
line 10,
hp,0.01 vs. line 10,
ip,0.001 vs. line 10
doi:10.1371/journal.pone.0000789.t003
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Table 4. Muscle weights (mg) following transfer of newborn mice to foster mothers.
..................................................................................................................................................
Mstn sex parents foster mother n pectoralis triceps quadriceps gastrocnemius
+/+ F Mstn
+/+ Mstn
+/+ 8 47.861.4 66.061.1 143.364.2 97.062.5
+/+ F Mstn
+/+ Mstn
2/2 19 47.960.9 66.860.7 143.261.9 97.161.2
+/+ M Mstn
+/+ Mstn
+/+ 10 73.762.5 92.963.0 191.067.4 129.364.3
+/+ M Mstn
+/+ Mstn
2/2 15 74.561.6 91.561.8 192.863.6 129.661.9
2/2 F Mstn
2/2 Mstn
+/+ 13 115.962.9 156.663.3 280.867.2 191.864.2
2/2 F Mstn
2/2 Mstn
2/2 11 110.561.9 150.562.1 281.064.8 194.562.9
2/2 M Mstn
2/2 Mstn
+/+ 15 189.565.0 215.965.3 376.267.2 260.364.8
2/2 M Mstn
2/2 Mstn
2/2 14 193.563.7 218.464.5 385.467.3 267.265.0
doi:10.1371/journal.pone.0000789.t004
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PLoS ONE | www.plosone.org 5 August 2007 | Issue 8 | e789response to specific physiological stimuli, such as injury, and
a second to regulate the overall metabolic balance between fat and
muscle in response to general physiological stimuli, such as
nutritional status [1]. According to this model, local control of
muscle growth would be achieved by regulating the extent to
which the latent form of myostatin is activated at the target site,
whereas global control of the metabolic homeostatic balance
between muscle and other tissues would be achieved by regulating
the size of the circulating pool of myostatin.
The second important finding presented here is the demonstra-
tion that other ligands work with myostatin to control muscle
growth. I have presented data showing that FLRG, like follistatin,
can promote muscle growth when expressed as a transgene in
skeletal muscle and that both of these molecules appear to act by
blocking not only myostatin but also other ligands with similar
activity to myostatin. By combining the follistatin transgene with
a myostatin null mutation, I have been able to generate mice with
quadrupled muscle mass, which represents yet another doubling of
muscle mass compared to mice only lacking myostatin. These
studies demonstrate that muscle mass in mice is controlled by
multiple members of the transforming growth factor-ß superfamily
acting in concert. We reached a similar conclusion in an earlier
study in which we demonstrated that administration of a soluble
form of the ACVR2B receptor to wild type could cause more
extensive muscle growth than what had been observed previously
using myostatin-specific inhibitors and that this soluble receptor
could also increase muscle growth even in mice completely lacking
myostatin [7]. The studies presented here demonstrate that the
capacity for promoting muscle growth by targeting this general
signaling pathway is far greater than previously appreciated.
Because myostatin normally acts to limit muscle growth, there
has been considerable interest in targeting this pathway to attempt
to enhance muscle growth in human patients with muscle wasting
and muscle degenerative diseases. Most efforts in this regard have
focused on agents capable of binding specifically to myostatin and
inhibiting its activity. The finding that myostatin is not the sole
regulator of muscle mass in mice raises the question as to whether
targeting myostatin alone will be the most effective strategy for
manipulating this signaling pathway in humans. In this respect, it
is known that the circulating levels of myostatin protein in humans
are considerably lower than in mice [14,21], raising the possibility
that the balance of the relative roles played by myostatin and by
these other regulators may have shifted further away from
myostatin in humans compared to mice. For these reasons, it will
be essential to determine the identity of the other ligand or ligands
that cooperate with myostatin, as only then will we be able to
develop the best possible strategies for manipulating this pathway
for the treatment of human diseases in which promoting muscle
growth may be beneficial.
MATERIALS AND METHODS
Pronuclear injections of DNA and embryo transfers were carried
out by the Johns Hopkins Transgenic Core Facility. Mstn mutant
and F66 and FLRG transgenic mice were backcrossed at least 6
times onto a C57 BL/6 background prior to analysis. All analysis
was carried out on 10 week old mice. For measurement of muscle
weights, individual muscles from both sides of the animal were
dissected, and the average weight was used for each muscle. For
morphometric analysis, the gastrocnemius and plantaris muscles
were sectioned serially to their widest point using a cryostat, and
fiber diameters were measured (as the shortest distance across the
fiber passing through the midpoint) from hematoxylin and eosin
stained sections. Measurements were carried out on 250 fibers per
animal, and all data for a given genotype were pooled.
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